| |
Voluntary Licensing Agreements for Remdesivir Gilead Announcement
|
| |
| |
https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir. The agreements allow the companies – Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan – to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access.
Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding COVID-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, whichever is earlier.
Here's a list of the 127 countries that will get the drug.
Gilead strikes deal to make remdesivir coronavirus treatment in 127 countries
Published Tue, May 12 2020 4;17 pm
https://www.cnbc.com/2020/05/12/remdesivir-coronavirus-treatment-gilead-strikes-deal-to-make-drug-in-127-countries.html
• Gilead Sciences has struck a licensing agreement with five generic drugmakers to make antiviral drug remdesivir in 127 countries, not including the United States.
• The deal is "royalty-free" until WHO says the Covid-19 outbreak is no longer a global health crisis or "until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19."
Gilead Sciences has struck a licensing agreement with five generic drugmakers to make antiviral drug remdesivir in 127 countries, not including the United States, the company announced Tuesday.
Drugmakers Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences will manufacture remdesivir for distribution in "low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries" that face health-care obstacles amid the coronavirus pandemic, the company said.
The deal is "royalty-free" until the World Health Organization says the Covid-19 outbreak is no longer a global health crisis or "until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier," the company said.
The Food and Drug Administration on May 1 granted emergency use authorization for Gilead's remdesivir drug to treat Covid-19, which has infected more than 4 million people across the globe in a little over four months, according to data compiled by Johns Hopkins University.
The intravenous drug has helped shorten the recovery time of some hospitalized Covid-19 patients, new clinical trial data suggests. Without other proven treatments, physicians will likely be considering its use to treat the coronavirus.
Here's a list of the 127 countries that will get the drug.
Gilead announces non-U.S. deals with five generic drugmakers for remdesivir
Published: May 12, 2020
drugmaker listed on its website five generic drugmakers that will produce remdesivir, its experimental COVID-19 treatment. The non-exclusive voluntary licensing agreements are with Cipla Ltd, Ferozsons Laboratories Ltd, Hetero Labs Ltd., Jubilant Life Sciences Ltd., and Mylan, to manufacture remdesivir in 127 countries.
The Food and Drug Administration recently granted an emergency authorization to remdesivir in the U.S. as a treatment for severely ill COVID-19 patients; it has also been approved in Japan. Neither nation is part of these manufacturing agreements. China, where the virus was first detected in 2019, also isn't listed. Gilead said the licenses will be considered royalty-free until one of two things happens: the World Health Organization lifts its public health emergency of international concern declaration, or another drug or vaccine is approved.
|
|
| |
| |
|
|
|
